PL1843749T3 - Kompozycje o kontrolowanym uwalnianiu dla interferonu na bazie kopolimerów blokowych PEGT/PBT - Google Patents

Kompozycje o kontrolowanym uwalnianiu dla interferonu na bazie kopolimerów blokowych PEGT/PBT

Info

Publication number: PL1843749T3
Authority: PL; Poland
Prior art keywords: composition; pegt; controlled release; block copolymers; release compositions
Prior art date: 2005-01-07

Application number

PL06700417T

Other languages

English (en)

Inventor

Anne Chantal Bechet

Dijkhuizen-Radersma Riemke Van

Martin Stigter

Jeroen Mattijs Bezemer

Original Assignee

Biolex Therapeutics Inc

Octoplus Polyactive Sciences B V

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-07

Filing date

2006-01-06

Publication date

2009-10-30

2006-01-06 Application filed by Biolex Therapeutics Inc, Octoplus Polyactive Sciences B V filed Critical Biolex Therapeutics Inc

2009-10-30 Publication of PL1843749T3 publication Critical patent/PL1843749T3/pl

Links

239000000203 mixture Substances 0.000 title abstract 5
102000014150 Interferons Human genes 0.000 title abstract 2
108010050904 Interferons Proteins 0.000 title abstract 2
229920001400 block copolymer Polymers 0.000 title abstract 2
238000013270 controlled release Methods 0.000 title abstract 2
229940079322 interferon Drugs 0.000 title 1
-1 poly(ethylene glycol) Polymers 0.000 abstract 4
229920001707 polybutylene terephthalate Polymers 0.000 abstract 2
230000000975 bioactive effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000007943 implant Substances 0.000 abstract 1
229940047124 interferons Drugs 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000011859 microparticle Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229920001223 polyethylene glycol Polymers 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1
KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 abstract 1
231100000331 toxic Toxicity 0.000 abstract 1
230000002588 toxic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Zoology (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Biotechnology (AREA)
Hematology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL06700417T 2005-01-07 2006-01-06 Kompozycje o kontrolowanym uwalnianiu dla interferonu na bazie kopolimerów blokowych PEGT/PBT PL1843749T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP05075043A EP1679065A1 (en)	2005-01-07	2005-01-07	Controlled release compositions for interferon based on PEGT/PBT block copolymers
EP06700417A EP1843749B1 (en)	2005-01-07	2006-01-06	Controlled release compositions for interferon based on pegt/pbt block copolymers
PCT/NL2006/000006 WO2006085747A1 (en)	2005-01-07	2006-01-06	Controlled release compositions for interferon based on pegt/pbt block copolymers

Publications (1)

Publication Number	Publication Date
PL1843749T3 true PL1843749T3 (pl)	2009-10-30

Family

ID=34937981

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06700417T PL1843749T3 (pl)	2005-01-07	2006-01-06	Kompozycje o kontrolowanym uwalnianiu dla interferonu na bazie kopolimerów blokowych PEGT/PBT

Country Status (23)

Country	Link
US (3)	US7736674B2 (pl)
EP (4)	EP1679065A1 (pl)
JP (2)	JP2008526837A (pl)
KR (2)	KR101354521B1 (pl)
CN (2)	CN101137349B (pl)
AT (1)	ATE431134T1 (pl)
AU (2)	AU2006213168B2 (pl)
BR (1)	BRPI0606514A2 (pl)
CA (1)	CA2594434A1 (pl)
CY (1)	CY1109297T1 (pl)
DE (1)	DE602006006797D1 (pl)
DK (1)	DK1843749T3 (pl)
ES (1)	ES2327267T3 (pl)
HR (1)	HRP20090434T1 (pl)
IL (2)	IL184431A (pl)
MX (1)	MX2007008293A (pl)
PL (1)	PL1843749T3 (pl)
PT (1)	PT1843749E (pl)
RS (1)	RS51129B (pl)
RU (2)	RU2409348C2 (pl)
SG (1)	SG158856A1 (pl)
SI (1)	SI1843749T1 (pl)
WO (1)	WO2006085747A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1679065A1 (en)	2005-01-07	2006-07-12	OctoPlus Sciences B.V.	Controlled release compositions for interferon based on PEGT/PBT block copolymers
CA2694440A1 (en) *	2007-07-25	2009-01-29	Biolex Therapeutics, Inc.	Controlled release interferon drug products and treatment of hcv infection using same
CN102215821B (zh)	2007-10-23	2013-05-08	皇家飞利浦电子股份有限公司	用于制备聚合物微颗粒的方法
EP2055299A1 (en) *	2007-10-23	2009-05-06	Koninklijke Philips Electronics N.V.	Methods for preparing polymer microparticles
BRPI0910198A2 (pt) *	2008-06-30	2016-01-12	Silenseed Ltd	composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo.
CN102413843A (zh)	2009-03-05	2012-04-11	阿森迪斯药物股份有限公司	干扰素α载体前药
US20120244222A1 (en) *	2011-03-25	2012-09-27	Selecta Biosciences, Inc.	Osmotic mediated release synthetic nanocarriers
CN104023726A (zh)	2011-10-21	2014-09-03	艾伯维公司	用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
DE112012003510T5 (de)	2011-10-21	2015-03-19	Abbvie Inc.	Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
SMT202100481T1 (it)	2014-08-18	2021-09-14	Alkermes Pharma Ireland Ltd	Composizioni per profarmaci di aripiprazolo
WO2016046817A1 (en)	2014-09-24	2016-03-31	Vital Beverages Global Inc.	Compositions and methods for selective gi tract delivery
JP7129703B2 (ja)	2016-04-28	2022-09-02	エモリーユニバーシティー	アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN114096234A (zh)	2019-07-12	2022-02-25	巴斯夫欧洲公司	生产载有挥发性有机活性物的微粒的方法
AU2024389329A1 (en) *	2023-11-28	2026-07-09	Abion Inc.	Novel use of interferon epsilon

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL137652C (pl) *	1962-07-11
US5372808A (en) *	1990-10-17	1994-12-13	Amgen Inc.	Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5192743A (en) *	1992-01-16	1993-03-09	Genentech, Inc.	Reconstitutable lyophilized protein formulation
ATE227963T1 (de)	1992-04-24	2002-12-15	Osteotech Inc	Vorrichtung zum vermeiden von gewebeadhäsionen
US5711968A (en) *	1994-07-25	1998-01-27	Alkermes Controlled Therapeutics, Inc.	Composition and method for the controlled release of metal cation-stabilized interferon
ATE161716T1 (de)	1992-08-07	1998-01-15	Takeda Chemical Industries Ltd	Herstellung von mikrokapseln, die wasserlösliche arzneimittel enthalten
US5643605A (en)	1993-10-25	1997-07-01	Genentech, Inc.	Methods and compositions for microencapsulation of adjuvants
US6117455A (en)	1994-09-30	2000-09-12	Takeda Chemical Industries, Ltd.	Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US5612052A (en)	1995-04-13	1997-03-18	Poly-Med, Inc.	Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
DE19545257A1 (de)	1995-11-24	1997-06-19	Schering Ag	Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
CN101028523A (zh) *	1995-11-30	2007-09-05	德克萨斯州立大学董事会	诊断和治疗肿瘤的方法及组合物
US5792477A (en)	1996-05-07	1998-08-11	Alkermes Controlled Therapeutics, Inc. Ii	Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5980948A (en) *	1996-08-16	1999-11-09	Osteotech, Inc.	Polyetherester copolymers as drug delivery matrices
EP2030614A1 (en) *	1997-02-27	2009-03-04	Novartis AG	Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin
AU7134898A (en) *	1997-04-17	1998-11-11	Amgen, Inc.	Biodegradable microparticles for the sustained delivery of therapeutic drugs
AR012448A1 (es)	1997-04-18	2000-10-18	Ipsen Pharma Biotech	Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6531154B1 (en)	1997-06-10	2003-03-11	Brown University Research Foundation	Modulated release from biocompatible polymers
HUP0004169A3 (en) *	1997-10-24	2001-06-28	Lilly Co Eli	Insoluble insulin compositions and process for production thereof
US6270802B1 (en)	1998-10-28	2001-08-07	Oakwood Laboratories L.L.C.	Method and apparatus for formulating microspheres and microcapsules
US6194006B1 (en)	1998-12-30	2001-02-27	Alkermes Controlled Therapeutics Inc. Ii	Preparation of microparticles having a selected release profile
CA2360232A1 (en) *	1999-01-12	2000-07-20	Tamio Mizukami	Telomerase inhibitors
US6204308B1 (en)	1999-03-01	2001-03-20	Novartis Ag	Organic compounds
US20030206928A1 (en) *	1999-04-07	2003-11-06	Pertti Tormala	Bioactive, bioabsorbable surgical polyethylene glycol and polybutylene terephtalate copolymer composites and devices
US6291013B1 (en)	1999-05-03	2001-09-18	Southern Biosystems, Inc.	Emulsion-based processes for making microparticles
HK1042237A1 (en)	1999-07-15	2002-08-09	Takeda Chemical Industries, Ltd.	Sustained release compositions, process for producing the same and use thereof
EP1090928B1 (en)	1999-09-30	2004-05-26	Chienna B.V.	Polymers loaded with bioactive agents
US6465425B1 (en) *	2000-02-10	2002-10-15	Alkermes Controlled Therapeutics, Inc.	Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6495164B1 (en)	2000-05-25	2002-12-17	Alkermes Controlled Therapeutics, Inc. I	Preparation of injectable suspensions having improved injectability
US6479065B2 (en)	2000-08-10	2002-11-12	Alkermes Controlled Therapeutics, Inc.	Process for the preparation of polymer-based sustained release compositions
US6471995B1 (en)	2000-09-27	2002-10-29	Alkermes Controlled Therapeutics, Inc. Ii	Apparatus and method for preparing microparticles using liquid-liquid extraction
JP4557409B2 (ja) *	2000-11-13	2010-10-06	日東電工株式会社	多孔質ポリイミドの製造方法及び多孔質ポリイミド
ES2250502T3 (es)	2000-12-13	2006-04-16	Merckle Gmbh	Microparticulas con un perfil de liberacion mejorado y procedimient0 para su preparacion.
EP1356809A4 (en)	2000-12-28	2008-05-14	Takeda Pharmaceutical	Sustained release preparations
RU2191012C1 (ru) *	2001-06-20	2002-10-20	Научно-исследовательский испытательный центр (медико-биологической защиты) Государственного научно-исследовательского испытательного института военной медицины МО РФ	Глазные капли для лечения эндотелиально-эпителиальной дистрофии роговицы
JP2005508220A (ja) *	2001-10-24	2005-03-31	パーリ・ゲーエムベーハー	薬用組成物調製用具
CA2466998A1 (en) *	2001-11-12	2003-05-22	Alkermes Controlled Therapeutics, Inc.	Biocompatible polymer blends and uses thereof
TWI252111B (en)	2001-12-14	2006-04-01	Solvay Pharm Gmbh	Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
CN1620285A (zh)	2001-12-26	2005-05-25	武田药品工业株式会社	新微球和其生产方法
KR101041767B1 (ko)	2002-06-25	2011-06-17	다케다 야쿠힌 고교 가부시키가이샤	서방성 조성물의 제조 방법
AU2004259208B2 (en)	2003-07-15	2011-04-28	Evonik Corporation	Method for the preparation of controlled release formulations
CN1968700A (zh)	2004-04-15	2007-05-23	阿尔克姆斯有限公司	聚合物基的持续释放装置
EP1679065A1 (en)	2005-01-07	2006-07-12	OctoPlus Sciences B.V.	Controlled release compositions for interferon based on PEGT/PBT block copolymers

2005
- 2005-01-07 EP EP05075043A patent/EP1679065A1/en not_active Withdrawn
2006
- 2006-01-06 SG SG201000063-6A patent/SG158856A1/en unknown
- 2006-01-06 RU RU2007130090/15A patent/RU2409348C2/ru not_active IP Right Cessation
- 2006-01-06 BR BRPI0606514-7A patent/BRPI0606514A2/pt not_active IP Right Cessation
- 2006-01-06 PT PT06700417T patent/PT1843749E/pt unknown
- 2006-01-06 AU AU2006213168A patent/AU2006213168B2/en not_active Ceased
- 2006-01-06 MX MX2007008293A patent/MX2007008293A/es active IP Right Grant
- 2006-01-06 EP EP06700417A patent/EP1843749B1/en not_active Expired - Lifetime
- 2006-01-06 KR KR1020107020687A patent/KR101354521B1/ko not_active Expired - Fee Related
- 2006-01-06 EP EP10182460A patent/EP2266535B1/en not_active Expired - Lifetime
- 2006-01-06 CN CN200680007430XA patent/CN101137349B/zh not_active Expired - Fee Related
- 2006-01-06 RS RSP-2009/0358A patent/RS51129B/sr unknown
- 2006-01-06 DK DK06700417T patent/DK1843749T3/da active
- 2006-01-06 SI SI200630366T patent/SI1843749T1/sl unknown
- 2006-01-06 AT AT06700417T patent/ATE431134T1/de active
- 2006-01-06 EP EP07120539A patent/EP1886668B1/en not_active Expired - Lifetime
- 2006-01-06 HR HR20090434T patent/HRP20090434T1/hr unknown
- 2006-01-06 CA CA002594434A patent/CA2594434A1/en not_active Abandoned
- 2006-01-06 CN CN200910207704A patent/CN101791396A/zh active Pending
- 2006-01-06 PL PL06700417T patent/PL1843749T3/pl unknown
- 2006-01-06 JP JP2007550316A patent/JP2008526837A/ja active Pending
- 2006-01-06 WO PCT/NL2006/000006 patent/WO2006085747A1/en not_active Ceased
- 2006-01-06 DE DE602006006797T patent/DE602006006797D1/de not_active Expired - Lifetime
- 2006-01-06 ES ES06700417T patent/ES2327267T3/es not_active Expired - Lifetime
- 2006-01-06 KR KR1020077018068A patent/KR20070118225A/ko not_active Ceased
2007
- 2007-07-05 IL IL184431A patent/IL184431A/en not_active IP Right Cessation
- 2007-07-06 US US11/774,107 patent/US7736674B2/en not_active Expired - Fee Related
2009
- 2009-05-15 US US12/466,430 patent/US7867518B2/en not_active Expired - Fee Related
- 2009-08-10 CY CY20091100844T patent/CY1109297T1/el unknown
- 2009-11-25 US US12/625,929 patent/US8163307B2/en not_active Expired - Fee Related
2010
- 2010-09-14 JP JP2010205413A patent/JP4887542B2/ja not_active Expired - Fee Related
- 2010-09-15 IL IL208175A patent/IL208175A0/en unknown
- 2010-09-20 RU RU2010138739/15A patent/RU2010138739A/ru unknown
- 2010-09-24 AU AU2010224413A patent/AU2010224413B2/en not_active Ceased

Also Published As

Publication number	Publication date
AU2010224413B2 (en)	2012-03-22
EP1886668A1 (en)	2008-02-13
EP2266535A2 (en)	2010-12-29
EP1679065A1 (en)	2006-07-12
RS51129B (sr)	2010-10-31
JP4887542B2 (ja)	2012-02-29
CY1109297T1 (el)	2014-07-02
EP2266535A3 (en)	2011-06-15
CN101137349A (zh)	2008-03-05
MX2007008293A (es)	2007-12-07
SG158856A1 (en)	2010-02-26
US8163307B2 (en)	2012-04-24
EP1843749A1 (en)	2007-10-17
ES2327267T3 (es)	2009-10-27
AU2010224413A1 (en)	2010-10-14
US20090226532A1 (en)	2009-09-10
US20080008733A1 (en)	2008-01-10
EP2266535B1 (en)	2013-03-06
KR20100109983A (ko)	2010-10-11
RU2010138739A (ru)	2012-03-27
EP1886668B1 (en)	2012-11-14
CA2594434A1 (en)	2006-08-17
PT1843749E (pt)	2009-08-17
DE602006006797D1 (de)	2009-06-25
EP1843749B1 (en)	2009-05-13
RU2007130090A (ru)	2009-02-20
IL184431A0 (en)	2007-10-31
CN101791396A (zh)	2010-08-04
JP2008526837A (ja)	2008-07-24
US20100074868A1 (en)	2010-03-25
IL184431A (en)	2012-03-29
AU2006213168B2 (en)	2011-09-15
SI1843749T1 (sl)	2009-10-31
US7736674B2 (en)	2010-06-15
AU2006213168A1 (en)	2006-08-17
IL208175A0 (en)	2010-12-30
RU2409348C2 (ru)	2011-01-20
BRPI0606514A2 (pt)	2010-01-19
WO2006085747A1 (en)	2006-08-17
ATE431134T1 (de)	2009-05-15
HK1152644A1 (en)	2012-03-09
JP2011016836A (ja)	2011-01-27
US7867518B2 (en)	2011-01-11
KR20070118225A (ko)	2007-12-14
DK1843749T3 (da)	2009-09-07
CN101137349B (zh)	2013-01-02
KR101354521B1 (ko)	2014-01-22
HRP20090434T1 (hr)	2009-09-30

Publication	Publication Date	Title
IL184431A0 (en)	2007-10-31	Controlled release compositions for interferon based on pegt-pbt block copolymers
WO2007127440A3 (en)	2008-12-04	Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
PL2348114T3 (pl)	2019-08-30	Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
NZ600958A (en)	2015-05-29	Methods and compositions for live attentuated viruses
EP1721625A3 (en)	2008-11-05	Biodegradable medical devices with enhanced mechanical strength and pharmacological functions
MXPA05003394A (es)	2005-10-05	Conjugados de polimero con antigenicidad disminuida, metodos de preparacion y usos de estos.
IL188774A0 (en)	2008-04-13	Compositions for delivery of drug combinations
WO2007050387A3 (en)	2007-12-06	Keratin bioceramic compositions
WO2006105172A3 (en)	2007-11-01	Peg-polyacetal and peg-polyacetal-poe graft copolymers and pharmaceutical compositions
TNSN06071A1 (en)	2007-10-03	Use of modified cyclosporins for the treatment of hcv disorders
IL213319A (en)	2017-07-31	Polylysis peptides for use in the treatment of bacterial infections
MXPA03010103A (es)	2004-03-10	Peptidos y composiciones anti-microbianos.
MXPA03008886A (es)	2003-12-08	Composiciones de baja respuesta glicemica.
LU91989I9 (pl)	2019-01-03
UA95225C2 (ru)	2011-07-25	Модифицированный полимером фактор viii для лечения гемофилии, способ его получения
WO2004093795A3 (en)	2005-04-07	Compositions for delivery of drug combinations
EP1884159A3 (en)	2010-02-24	Synergistic microbicidal composition comprising N-alkyl-1,2-benzisothiazolin-3-one and caprylyl glycol
EA200700435A1 (ru)	2007-10-26	Рентгеноконтрастные полимерные стенты
EP2360180A3 (en)	2012-02-08	Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
LT1848761T (lt)	2021-04-12	Poliesterio polimero ir kopolimero kompozicijos, turinčios titano nitrido dalelių
WO2005032453A3 (en)	2007-02-08	Antiviral agents for the treatment, control and prevention of infections by coronaviruses
AU2003251728A8 (en)	2004-01-19	Placental growth factor as a target for the treatment of osteoporosis
PL1633440T3 (pl)	2008-12-31	Kompozycja farmaceutyczna zawierająca białka i/lub polipeptydy oraz cząstki koloidalne
AU2003208197A8 (en)	2003-09-16	Use of soluble fgl2 as an immunosuppressant
MX2007007200A (es)	2007-08-15	Composiciones de tratamiento oral que contienen un agente anti-adhesion, un agente antibacterial, y un compuesto incompatible.